Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc., a clinical-stage biopharmaceutical company, reported revenue of $422K in Q2, a significant increase from $197K in Q1, indicating a strong upward trend. The company is projected to experience robust revenue growth, with expectations of reaching $1.3 million in 2025 and $4.5 million in 2026, reflecting the market's potential for its innovative therapies. Given the high unmet medical needs in cancer treatment and the company’s proprietary Trans-Arterial Micro-Perfusion therapy platform, the fundamentals suggest a positive outlook for future financial performance.

Bears say

RenovoRx Inc's financial metrics exhibit a concerning trend, with reported revenue of only $0.3 million to $0.4 million, while sustaining a significant net loss of $2.9 million, resulting in an earnings per share (EPS) of $(0.08). The company's focus on developing therapies for pancreatic cancer, a disease with a dismal 5-year survival rate of 12%, raises questions regarding the potential market viability and patient impact of its treatments. Furthermore, despite growth prospects, the persistently high losses and minimal revenue generation indicate a substantial risk that could deter investment in the company's stock.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.